Answers are grounded in this paper and cite their sources.
Sensitive quantification of low-abundance biomarkers in noninvasive biofluids is critical for advancing Alzheimer’s disease (AD) diagnostics. In this study, we developed an electrochemical immunosensor for the detection of amyloid β 1–42 (Aβ1–42) in human saliva using disposable gold screen-printed electrodes (AuSPEs). The sensing interface was fabricated through covalent antibody immobilization on a cysteamine-modified gold surface to enable selective electrochemical recognition of Aβ1–42. Under optimized conditions, the immunosensor exhibited a linear response over the concentration range of 10–40 pg/mL with a limit of detection of 5.39 pg/mL and good selectivity toward structurally related peptides. To reduce matrix-associated signal variability during saliva analysis, a simple PBS dilution protocol was applied, resulting in reduced intersubject signal variability compared with untreated saliva samples (SD ≤ 3.05 μA) and a strong correlation with PBS measurements (R2 = 0.9962). The developed platform demonstrated the feasibility of electrochemical detection of low-abundance Aβ1–42 in diluted human saliva using disposable electrodes. Furthermore, pilot application using 25 human saliva specimens demonstrated strong linear concordance with a commercial ELISA benchmark (R2 = 0.9817), supporting the analytical reliability and preliminary feasibility of this noninvasive platform for salivary Aβ1–42 measurement.
No takes yet. Share an insight, caveat, or question.
Vutipow et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: